Abstract
Fifty-seven previously untreated adult acute myeloid leukemia patients received idarubicin (IDA) in sequential combination with cytarabine as induction therapy; post-remission treatment included two courses of IDA and cytarabine alternating with two courses of VP-16 and cytarabine. As late intensification, patients received either high-dose cytarabine or, in 10 cases, autologous bone marrow transplantation. Complete remission (CR) was achieved in 48 patients (84.2%), 41 after one induction course and seven after two courses. Median length of disease-free survival (DFS) was 26 months. Univariate analysis did not identify any of the investigated variables as having prognostic significance in predicting DFS. On the other hand, patients achieving CR after one induction course had a better DFS than those requiring two courses. Furthermore, the analysis of DFS slightly favors autologous bone marrow transplantation. In conclusion, the antileukemic activity of the present IDA protocol is testified by the high CR rate and by the possibility of minimizing the role of prognostic factors. The better outcome of patients achieving CR after one induction course further supports the opinion that the intensity of the induction treatment, offered by an agent as potent as IDA, might significantly influence DFS.
| Original language | English |
|---|---|
| Pages (from-to) | 27-33 |
| Number of pages | 7 |
| Journal | Seminars in Oncology |
| Volume | 20 |
| Issue number | SUPPL. 8 |
| Publication status | Published - 1993 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Idarubicin in the therapy of acute myeloid leukemia : Final analysis in 57 previously untreated patients. / Deliliers, G. L.; Annaloro, C.; Oriani, A.; Pozzoli, E.; Cortelezzi, A.; Cortellaro, M.; Mozzana, R.; Volpe, A. D.; Soligo, D.; Cofrancesco, E.; Boschetti, C.; Polli, E. E.
In: Seminars in Oncology, Vol. 20, No. SUPPL. 8, 1993, p. 27-33.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Idarubicin in the therapy of acute myeloid leukemia
T2 - Final analysis in 57 previously untreated patients
AU - Deliliers, G. L.
AU - Annaloro, C.
AU - Oriani, A.
AU - Pozzoli, E.
AU - Cortelezzi, A.
AU - Cortellaro, M.
AU - Mozzana, R.
AU - Volpe, A. D.
AU - Soligo, D.
AU - Cofrancesco, E.
AU - Boschetti, C.
AU - Polli, E. E.
PY - 1993
Y1 - 1993
N2 - Fifty-seven previously untreated adult acute myeloid leukemia patients received idarubicin (IDA) in sequential combination with cytarabine as induction therapy; post-remission treatment included two courses of IDA and cytarabine alternating with two courses of VP-16 and cytarabine. As late intensification, patients received either high-dose cytarabine or, in 10 cases, autologous bone marrow transplantation. Complete remission (CR) was achieved in 48 patients (84.2%), 41 after one induction course and seven after two courses. Median length of disease-free survival (DFS) was 26 months. Univariate analysis did not identify any of the investigated variables as having prognostic significance in predicting DFS. On the other hand, patients achieving CR after one induction course had a better DFS than those requiring two courses. Furthermore, the analysis of DFS slightly favors autologous bone marrow transplantation. In conclusion, the antileukemic activity of the present IDA protocol is testified by the high CR rate and by the possibility of minimizing the role of prognostic factors. The better outcome of patients achieving CR after one induction course further supports the opinion that the intensity of the induction treatment, offered by an agent as potent as IDA, might significantly influence DFS.
AB - Fifty-seven previously untreated adult acute myeloid leukemia patients received idarubicin (IDA) in sequential combination with cytarabine as induction therapy; post-remission treatment included two courses of IDA and cytarabine alternating with two courses of VP-16 and cytarabine. As late intensification, patients received either high-dose cytarabine or, in 10 cases, autologous bone marrow transplantation. Complete remission (CR) was achieved in 48 patients (84.2%), 41 after one induction course and seven after two courses. Median length of disease-free survival (DFS) was 26 months. Univariate analysis did not identify any of the investigated variables as having prognostic significance in predicting DFS. On the other hand, patients achieving CR after one induction course had a better DFS than those requiring two courses. Furthermore, the analysis of DFS slightly favors autologous bone marrow transplantation. In conclusion, the antileukemic activity of the present IDA protocol is testified by the high CR rate and by the possibility of minimizing the role of prognostic factors. The better outcome of patients achieving CR after one induction course further supports the opinion that the intensity of the induction treatment, offered by an agent as potent as IDA, might significantly influence DFS.
UR - http://www.scopus.com/inward/record.url?scp=0027769489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027769489&partnerID=8YFLogxK
M3 - Article
C2 - 8290969
AN - SCOPUS:0027769489
VL - 20
SP - 27
EP - 33
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - SUPPL. 8
ER -